Lenalidomide has proven efficacy and safety and has been shown to reduce transfusion requirements and reverse cytogenetic abnormalities in lower-risk myelodysplastic syndromes (MDS). However, ...
Hematopoietic stem and progenitor-cell (HSPC) neoplasms, such as myelodysplastic neoplasms (MDS), arise from the expansion of genetically altered HSPCs, commonly due to a multistep evolutionary ...
A phase 2 study of ofirnoflast showed 67% overall hematologic improvement and 55% transfusion independence in ESA-refractory lower-risk MDS.
Two abstracts presented at the 2024 American Society of Hematology Annual Meeting & Exhibition provided insight into MDS response to hypomethylating agents (HMAs). Patients with myelodysplastic ...
Molecular lesion data in LR-MDS prognostic models reduce the significance of traditional parameters like bone marrow blast percentage. Molecular data altered risk stratification for 30% of patients, ...
Younger patients with relapsed MDS may benefit from DLI post-stem cell transplant, improving overall survival rates. DLI is associated with graft-versus-host disease, but its impact on prognosis is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results